Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma

  • End date
    Apr 1, 2024
  • participants needed
  • sponsor
    Mingzhi Zhang
Updated on 23 January 2021


Comparison of the efficacy and safety of rituximab combined with fotemustine, pemetrexed, dexamethasone and rituximab in combination with methotrexate, cytarabine and dexamethasone as first-line regimens in the treatment of primary central nervous system lymphoma


This is an open, randomized, prospective, multicenter clinical study designed to compare the efficacy and safety of R-FPD and R-MAD as first-line regimens in the treatment of primary central nervous system lymphoma. A total of 20 patients plan to participate in the study. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS) and secondary endpoints including overall survival (OS), and adverse events.

Condition Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Primary CNS Lymphoma, cns lymphoma
Treatment rituximab in combination with methotrexate, cytarabine and dexamethasone
Clinical Study IdentifierNCT04083066
SponsorMingzhi Zhang
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Age 14-75 years old; KPS score 60 points or ECOG score 2 points; expected
survival period of more than 3 months; CD20 positive; PCNSL confirmed by
tissue biopsy pathology (limited to brain, spinal cord, meninges and eyes
without lymphoma involving other parts of the body); no chemotherapy
contraindications (blood and physiological examination results <7 days); At
least one measurable lesion according to the RECIST criteria; There are no
other serious diseases that conflict with this plan; There is a possibility of
follow-up; When using other anti-tumor drugs at different times during this
treatment, bisphosphonate anti-bone transfer therapy and other symptomatic
treatments may be applied; Can understand the situation of this study and sign
the informed consent form
Pathological histology is subject to consultation by pathologists at provincial hospitals

Exclusion Criteria

Currently receiving other chemotherapy, radiotherapy and targeted therapy
(chemotherapy within 3 weeks, radiotherapy within 2 weeks, or recovery from
acute toxicity of any previous treatment); Pregnant or lactating women; There
are any uncontrollable medical diseases (including active infection
uncontrolled diabetes, severe heart, liver, kidney dysfunction and
interstitial pneumonia); combined with chemotherapy and other
contraindications for chemotherapy; Those who have had other malignant tumors
in the past; There are uncontrolled infected patients; Those who have a
history of mental illness that is difficult to control; The investigator
believes that it is not appropriate to participate in this test
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note